Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease.
Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease.
复制标题
DOI：
10.4103/0976-9668.175016
复制
发表时间：
2016-01-01
期刊：
影响因子：
--
通讯作者：
Kakkar, Ashish Kumar
中科院分区：
文献类型：
--
作者：
Singh, Harmanjit;Grewal, Nipunjot;Kakkar, Ashish Kumar
炎症性肠病（IBD）是胃肠道的慢性炎症性疾病，包括两种亚型：溃疡性结肠炎和克罗恩病。 IBD是由于肠粘膜白细胞浸润和肠屏障功能紊乱而发生的。 IBD发病机制中最重要的步骤之一是白细胞表面整合素之间的相互作用。表达α4β7整合素的T细胞是参与发病机制的重要白细胞，代表了治疗IBD的新药物靶点。 Vedolizumab 是一种人源化单克隆抗体，作用于 α4β7 整合素异二聚体并阻断 α4β7 整合素与 MAdCAM-1 的相互作用。它可以防止白细胞与内皮表面结合及其外渗到受影响的组织中。维多珠单抗的有效性和安全性已在许多临床研究中得到证实。它在各种临床研究中显示出有希望的结果，与安慰剂相比，更多的患者达到并维持了临床反应、临床缓解和无皮质类固醇临床缓解。维多珠单抗已被证明具有良好的耐受性，与安慰剂相比，感染、头痛、鼻咽炎的风险略高。本综述重点关注维多珠单抗治疗 IBD 的潜在作用。
Inflammatory bowel disease (IBD) is the chronic inflammatory disorder of gastrointestinal tract consisting of two subtypes: Ulcerative colitis and Crohn's disease. IBD occurs due to infiltration of leukocytes in intestinal mucosa and derangements in intestinal barrier function. One of the most important steps in pathogenesis of IBD is the interactions between integrins on the surface of leukocyte. The alpha4beta7 integrin expressing T-cell is an important leukocyte involved in pathogenesis and represents a new drug target for the treatment of IBD. Vedolizumab is a humanized monoclonal antibody, which acts against alpha4beta7 integrin heterodimer and blocks the interaction of alpha4beta7 integrin with MAdCAM-1. It prevents leukocyte binding to endothelial surface and its extravasation into affected tissue. The efficacy and safety of the vedolizumab have been established in many clinical studies. It has shown promising results in various clinical studies where a greater percentage of patients as compared to a placebo achieved and maintained clinical response, clinical remission, and corticosteroid-free clinical remission. Vedolizumab has been shown to be well tolerated with slightly higher risk of infections, headache, naspharyngitis as compared to placebo. This review focuses on the potential role of vedolizumab for the treatment of IBD.